

Supplementary Appendix

This appendix has been provided by the authors to give readers additional information about their work.

Supplement to: Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. *N Engl J Med* 2020;383:1413-24. DOI: 10.1056/NEJMoa2022190

TABLE OF CONTENTS

Committees, Investigators, Criteria for Randomization and Adjudication

List of committees and investigators	p 2-4
List of principal investigators by country	p 5-14
Key inclusion and exclusion criteria	p 15-18
Major protocol-specific efficacy end points	p 19
Adjudicated outcome event definitions	p 20-26

Figures

Figure S1. Patient recruitment and disposition (CONSORT Diagram)	p 27
Figure S2. Cumulative incidence for time to first hospitalization for heart failure... p 28	
Figure S3. Cumulative incidence for time to cardiovascular death	p 29
Figure S4. Effect of region on the effect of treatment on primary end point	p 30
Figure S5. Cumulative incidence for time to death for any reason	p 31

Tables

Table S1. Reasons that screened patients were not randomized	p 32
Table S2. Selected adverse events of interest	p 33
Table S3. Sensitivity analyses of primary end point	p 34
Table S4. Comparison of baseline characteristics of the EMPEROR- Reduced and DAPA-HF trials	p 35

EMPEROR-REDUCED COMMITTEES AND INVESTIGATORS

EXECUTIVE COMMITTEE

Milton Packer MD (Chair), Baylor Heart and Vascular Institute Dallas, TX, USA and Imperial College, London, UK

Stefan Anker MD (Co-Chair), Berlin Institute of Health Center for Regenerative Therapies (BCRT); Berlin, Germany

Javed Butler MD, University of Mississippi Medical Center, Jackson, Mississippi, USA

Gerasimos Filippatos MD, National and Kapodistrian University of Athens School of Medicine, Athens, Greece

Stuart Pocock PhD, London School of Hygiene and Tropical Medicine, London, UK

Faiez Zannad MD, Université de Lorraine, Inserm INI-CRCT, CHRU, Nancy, France

Joao Pedro Ferreira MD, Université de Lorraine, Nancy, France

Martina Brueckmann MD, Boehringer Ingelheim International, Ingelheim, Germany

Jyothis George MD, Boehringer Ingelheim International, Ingelheim, Germany

Waheed Jamal, MD, Boehringer Ingelheim International, Ingelheim, Germany

DATA MONITORING COMMITTEE

Francine K. Welty MD, PhD (DMC Chair), Harvard Medical School, Boston, MA, USA

Mike Palmer BSc. FSS Ph.D (Independent Statistician), N Zero 1 Ltd, Wilmslow, Cheshire, UK

Tim Clayton, MSc (DMC Statistician), London School of Hygiene and Tropical Medicine, London, UK

Klaus G. Parhofer MD (DMC Member), University of Munich, Munich, Germany

Terje R. Pedersen MD, Oslo University Hospital, Ullevål and University of Oslo, Oslo, Norway

Barry Greenberg MD, UC San Diego Medical Center, La Jolla, CA, USA

Marvin A. Konstam MD, Tufts University School of Medicine, Tufts Medical Center, Boston, MA, USA

Kennedy R. Lees MD, University Department of Medicine and Therapeutics, Western Infirmary, Glasgow, UK

CLINICAL EVENT ADJUDICATION COMMITTEE

Peter Carson MD (Chairman), Washington DC Veterans Affairs Medical Center, Washington, DC, USA

Wolfram Doehner MD (Cardiology), Charite Universitätsmedizin Berlin Campus Virchow-Medical Center, Berlin, Germany

Alan Miller MD (Cardiology), University of Florida Health, Jacksonville, FL 32209 USA

Markus Haas MD (Cardiology), Theresienkrankenhaus, Mannheim, Germany
Steen Pehrson MD (Cardiology), University Hospital Rigshospitalet Blegdamsvej, Copenhagen, Denmark
Michel Komajda MD (Cardiology), Institut de Cardiologie, Boulevard de l'Hôpital, Paris, France
Inder Anand MD (Cardiology), University of Minnesota Medical School and VA Medical Center La Jolla, CA, USA
John Teerlink MD (Cardiology), University of California San Francisco Medical Center, SF, CA, USA
Alejandro Rabinstein MD (Neurology), Mayo Clinic College of Medicine, Rochester, MN, USA
Thorsten Steiner MD (Neurology), Klinikum Frankfurt Höchst, Frankfurt, Germany
Hooman Kamel MD (Neurology) Presbyterian Hospital/Weill Cornell Medical Center, New York, NY, USA
Georgios Tsvigoulis MD (Neurology), University of Tennessee Health Science Center, Memphis, TN USA
James Lewis MD (Hepatology), Georgetown University Hospital, Potomac, Maryland, USA
James Freston MD (Hepatology), Kiawah Island, SC 29455 USA
Neil Kaplowitz MD (Hepatology), University of Southern California Medical Center, Los Angeles, CA, USA
Johannes Mann MD (Endocrinology), University of Erlangen-Nürnberg Munich General Hospitals, Munich, Germany
John Petrie MD (Endocrinology), Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, Scotland

NATIONAL COORDINATORS

Sergio Perrone MD, Hospital El Cruce de Florencio Varela, Buenos Aires, Argentina
Stephen Nicholls MD, Monash Heart, Clayton, Victoria, Australia
Stefan Janssens MD, PhD, Universitair Ziekenhuis Leuven, Leuven, Belgium
Edmar Bocchi MD, Heart Institute of the University of Sao Paulo (InCor) Sao Paulo, Brazil
Nadia Giannetti MD, Centre Universitaire de Sante McGill, Montreal, QC Canada
Subodh Verma MD, PhD, St. Michael's Hospital, Toronto, Ontario, Canada
Jian Zhang MD, PhD, Fuwai Hospital Chinese Academic of Medical Science, Beijing, China
Jindrich Spinar MD, University Hospital, Masaryk University Hospital, Brno, Czech Republic
Marie-France Seronde MD, Centre Hospitalier Régional et Universitaire de Besançon, Besançon, France
Michael Boehm MD, PhD, Universitätsklinikum des Saarlandes und Medizinische Fakultät der Universität des Saarlandes, Homburg Germany
Bela Merkely MD, Heart and Vascular Center, Semmelweis University, Budapest, Hungary
Vijay Chopra MD, Medanta-The Medicity, Gurugram, India
Michele Senni MD, Ospedale Papa Giovanni XXIII, Bergamo, Italy

Stefano Taddi MD, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy
Hiroyuki Tsutsui MD, Kyushu University, Fukuoka City, Japan
Dong-Ju Choi MD, Seoul National University Bundang Hospital, Seoul, Republic of Korea
Eduardo Chuquiure MD, Instituto Nacional de Cardiologia Dr Ignacio Chavez Riera, Ciudad de Mexico
Hans Pieter Brunner La Rocca MD, Maastricht University Medical Center, Maastricht, Netherlands,
Piotr Ponikowski MD, Wroclaw Medical University, Wroclaw, Poland
Jose Ramon Gonzalez Juanatey MD, Complejo Hospitalario Universitario de Santiago, A Coruña, Spain
Iain Squire MD, University of Leicester, Glenfield General Hospital, Leicester, UK
James Januzzi MD, Harvard Medical School, Massachusetts General Hospital, Boston, MA USA
Ileana Pina MD, Detroit Medical Center Specialty Center- Heart Hospital, Detroit, MI USA

SCIENTIFIC ADVISORS

Richard Bernstein MD, Feinberg School of Medicine, Northwestern University, Chicago, USA
Alfred Cheung MD, University of Utah, Salt Lake City, USA
Jennifer Green MD, Duke University Hospital and Clinical Research Institute, Durham, USA
James Januzzi MD, Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA
Sanjay Kaul MD, Cedars-Sinai Medical Center, Los Angeles, USA
Carolyn Lam Su Ping MD, Yong Loo Lin School of Medicine, Singapore
Gregory Lip MD, University of Birmingham, Birmingham, UK
Nikolaus Marx MD, University Clinic RWTH Aachen, Aachen, Germany
Peter McCullough MD, Baylor University Medical Center, Dallas, USA
Cyrus Mehta MD, Harvard School of Public Health, Boston, USA
Piotr Ponikowski MD, Wroclaw Medical University, Wroclaw, Poland
Julio Rosenstock MD, Dallas Diabetes Research Center at Medical City and University of Texas Southwestern Medical Center, Dallas, USA
Naveed Sattar MD, University of Glasgow, Glasgow, UK
Benjamin Scirica MD, Harvard Medical School, Brigham and Women's Hospital, Boston, USA
Sanjiv Shah MD, Feinberg School of Medicine of Northwestern University, Chicago, USA
Hiroyuki Tsutsui MD, Kyushu University, Fukuoka City, Japan
Subodh Verma MD, PhD, St. Michael's Hospital, University of Toronto, Toronto, Canada
Christoph Wanner MD, University Clinic Wuerzburg, Wuerzburg, Germany

LIST OF PRINCIPAL INVESTIGATORS BY COUNTRY

Argentina

D. Aizenberg, Centro Medico Viamonte SRL, Buenos Aires, Ciudad Autónoma de Buenos Aires; L. Cartasegna, Hospita I Italiano de La Plata, La Plata, Buenos Aires; H. Colombo, Clinica Privada Colombo, Cordoba, Córdoba; M. Fernandez Moutin, Sanatorio Norte, Rosario, Santa Fe; J. Glenny, Glenny Corp. S.A. - Bioclinica Argentina, Ciudad Autónoma de Buenos Aires; C. Alvarez Lorio, Hospital Italiano Regional del Sur, Bahia Blanca, Buenos Aires; D. Anauch, Sanatorio Mayo Privado SA, Córdoba, Córdoba; R. Campos, Instituto Cardiovascular Buenos Aires, Ciudad Autonoma Buenos Aires, Buenos Aires; A. Facta, Hospital Privado de Comunidad, Mar del Plata, Buenos Aires; A. Fernandez, Instituto de Investigaciones Clinicas Quilmes, Quilmes, Buenos Aires; R. Ahuad Guerrero, Corporacion Medica de Gral. San Martin S.A., San Martin, Buenos Aires; L. Lobo Márquez; Instituto de Cardiología, San Miguel De Tucumán, Tucumán; R. Alfonso Leon de la Fuente, Centro Cardiovascular Salta, Salta; M. Mansilla, Clínica Mayo de Urgencias Medicas Cruz Blanca SRL, San Miguel de Tucuman, Tucuman; M. Hominal, Centro de Investigaciones Clínicas del Litoral, Santa Fe, Santa Fe; E. Hasbani, Investigaciones Clinicas Tucuman, San Miguel de Tucumán, Tucumán; M. Najenson, Instituto CAICI, Rosario, Santa Fe; H. Luquez, Centro Medico Luquez, San Vicente, Córdoba; L. Guzman, Instituto Médico DAMIC S.R.L., Cordoba, Córdoba; H. Sessa, Instituto Medico Fundación Grupo Colaborativo Rosario Investigación y Prevención Medica, Rosario, Santa Fe; Marcos Amuchástegui, Hospital Privado Centro Medico de Cordoba, Córdoba, Córdoba; O. Salomone, Hospital Privado Centro Medico de Cordoba, Córdoba, Córdoba; E. Perna, Instituto de Cardiología J.F Cabral, Corrientes, Corrientes; Daniel Piskorz, Sanatorio Britanico S.A., Rosario, Santa Fe; M. Sicer, Instituto de Investigaciones Clínicas Rosario, Rosario, Santa Fe; D. Perez de Arenaza, Hospital Italiano de Buenos Aires, CABA, Buenos Aires; C. Zaidman, CIPREC, Ciudad Autonoma Buenos Aires; S. Nani, Clínica Olivos, Vicente Lopez, Buenos Aires; C. Poy, Sanatorio Parque S.A., Rosario, Santa Fe; J. Resk, Centro de Investigaciones Clinicas Instituto del Corazon, Córdoba, Córdoba; R. Villarreal, Sanatorio Güemes, Ciudad Autonoma Buenos Aires; C. Majul, CEMEDIC - Centro de Especialidades Medicas, Villa Luro, Ciudad Autónoma de Buenos Aires; F. Colombo Berra, Instituto Médico CER, Quilmes, Buenos Aires; T. Smith Casabella, Prevencion Cardiovascular Salta, Salta, Salta; Sonia Sassone, Centro Medico Dra Laura Maffei, Ciudad Autonoma Buenos Aires; G. Carnero, Instituto Medico Elsa Perez SRL (IMEP), Ciudadela, Buenos Aires; A. Caccavo, Centro de Investigacion Clinica Coronel Suarez, Buenos Aires; M. Berli, Hospital Dr. Jose Maria Cullen, Santa Fé, Santa Fe; N. Budassi, Hospital Interzonal General de Agudos Dr Jose Penna, Bahia Blanca, Buenos Aires; J. Bono, Sanatorio Alle.nde, Córdoba, Córdoba; A. Alvarisqueta, Centro de Investigaciones Medicas Mar del Plata, Mar del Plata, Buenos Aires.

Australia

J. Amerena, The Geelong Hospital, Geelong, Victoria; K. Kostner, Mater Hospital Brisbane, South Brisbane, Queensland; A. Hamilton, Heart and Vascular Research, Fullarton., South Australia; A. Begg, SA Heart, Ashford, South Australia; D. Colquhoun, CORE Research Group, Milton, Queensland; A. Sverdlov, John Hunter Hospital, New Lambton, New South Wales; G. Vaddadi, The Northern Hospital, Epping, Victoria; J. Wong, Royal Melbourne Hospital, Parkville, Victoria; J. Collier, St Vincents Hospital Melbourne, Fitzroy, Victoria; D. Prior, St Vincents Hospital Melbourne, Fitzroy, Victoria .

Belgium

A. Friart, CHU de Tivoli, La Louvière; A. Leone, CHU de Tivoli, La Louvière; S. Janssens, UZ Leuven, Leuven; G. Vervoort, AZ Sint-Maarten Campus Leopoldstraat, Mechelen; P. Timmermans, Jessa Ziekenhuis - Campus Virga Jesse, Hasselt; T. Sarens, AZ Sint Blasius, Dendermonde; H.

Vandekerckhove, AZ Sint-Lucas, Gent; P. Van De Borne, Cliniques universitaires de Bruxelles - Hôpital Erasme, Bruxelles; F. Chenot, Grand Hôpital de Charleroi - Site Saint- Joseph, Gilly; J. De Sutter, A.Z. Maria Middelaers, Gent; E. De Vuyst, C.H.U. de Charleroi, Charleroi; P. Debonnaire, AZ Sint-Jan Brugge, Brugge; M. Dupont, Ziekenhuis Oost- Limburg - Campus Sint-Jan, Genk

Brazil

O. Pereira Dutra, Instituto de Cardiologia do Rio Grande do Sul, Porto Alegre; L.H. Canani, Centro de Pesquisas em Diabetes, Porto Alegre, Estado de Rio Grande do Sul; M. da Consolação Vieira Moreira, Hospital Felício Rocho, Belo Horizonte, Estado de Minas Gerais; W. de Souza, Via Médica, Goiania, Estado de Goiás; L. M. Backes, Hospital Sao Vicente de Paulo, Passo Fundo, Estado de Rio Grande do Sul; L. Maia, Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto, Sao Jose do Rio Preto, Estado de São Paulo; B. De Souza Paolino, CCBR Brasil Centro de Pesquisas e Análises Clínicas Ltda., Rio de Janeiro, Estado de Rio de Janeiro; E. R. Manenti, Hospital Universitário, Canoas, Estado de Rio Grande do Sul; Wladimir Saporito, Pesquisare. Santo André, Estado de São Paulo; F. Villaça Guimarães Filho, ICM - Instituto do Coração de Marília, Marília, Estado de São Paulo; T. Franco Hirakawa, Dr. Consulta, São Paulo, Estado de São Paulo; L. A. Saliba, Dr. Consulta, São Paulo, Estado de São Paulo; F. C. Neuenschwander, Hospital Vera Cruz, Belo Horizonte, Estado de Minas Gerais; C. A. de Freitas Zerbini, CEPIC - Centro Paulista de Investigacao Clinica e Servicos Medicos, Sao Paulo, Estado de São Paulo; G. Gonçalves; Hospital de Câncer de Barretos - Fundação Pio XII., Barretos, Estado de São Paulo; Y. Gonçalves Mello, CAEP - Centro Avançado de Estudos e Pesquisas Ltda., Campinas, Estado de São Paulo; J. Ascenção de Souza, CECAP - Centro de Cardiologia Clínica, Brasília, Distrito Federal; L. Beck da Silva Neto; Hospital de Clínicas de Porto Alegre; Porto Alegre, Estado de Rio Grande do Sul; E. A. Bocchi, INCOR - Hospital das Clínicas da Universidade de Sao Paulo, Sao Paulo, Estado de São Paulo; J. Da Silveira, CEMEC – Centro Multidisciplinar de Estudos Clínicos, São Bernardo do Campo, Estado de São Paulo; João Batista de Moura Xavier Moraes Junior, Hospital Agamenon Magalhaes, Recife, Estado de Pernambuco; João David de Souza Neto, Hospital de Messejana Dr. Carlos Alberto Studart Gomes, Fortaleza, Estado de Ceará; M. Hernandez, Santa Casa de Votuporanga, Votuporanga, Estado de São Paulo; H. Carlos Finimundi, IPCEM - Instituto de Pesquisa Clínica para Estudos Multicêntricos, - Universidade de Caxias do Sul, Caxias do Su, Estado de Rio Grande do Sul; C. R. Sampaio, CPCLIN - Centro de Pesquisas Clínicas Ltda., Sao Paulo, Estado de São Paulo; E. Vasconcellos, L2IP – Instituto de Pesquisas Clínicas Ltda., Brasília, Distrito Federal; F. J. Neves Mancuso; CDEC BRASIL - Centro de Desenvolvimento em Estudos Clínicos Brasil, São Paulo, Estado de São Paulo; M. M. Noya Rabelo, CTD – Clínica de Terapia da Dor, Salvador, Estado de Bahia; M. Rodrigues Bacci, Praxis Pesquisa Médica, Santo André, Estado de São Paulo; F. Santos, Loema - Instituto de Pesquisa Clínica, Campinas, Estado de São Paulo; M. Vidotti, Loema - Instituto de Pesquisa Clínica, Campinas, Estado de São Paulo; M. V. Simões, Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto – USP, R. Preto, Estado de São Paulo; F. L. Gomes, CEDOES - Diagnóstico e Pesquisa do Espírito Santo, Vitória, Estado de Espírito Santo; C. Vieira Nascimento, ICDF - Instituto de Cardiologia do Distrito Federal, Brasília, Distrito Federal; D. Precoma, Núcleo de Pesquisa Clínica em Cardiologia da Sociedade Hospitalar Angelina Caron; Campina Grande do Sul. Estado de Paraná; J. A. Ribas Fortes, PUC Trials - Núcleo de Pesquisa Clínica da Escola de Medicina da PUC-PR, Curitiba, Estado de Paraná; P. E. Leães, Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, Estado de Rio Grande do Sul; D. Campos de Albuquerque, HUPE-UERJ - Hospital Universitário Pedro Ernesto - Universidade Estadual do Rio de Janeiro, Rio de Janeiro, Estado de Rio de Janeiro; J.F. Kerr Saraiva, Hospital e Maternidade Celso Peirro – PUCCAMP, Campinas, Estado de São Paulo; Salvador Rassi, Departamento de clinica medica - sala de insuficiencia cardi, Goiania, Estado de Goiás; F. A. Alves da Costa, FGM - Clínica Paulista de Doenças Cardiovasculares, São Paulo, Estado de São Paulo; G. Reis, Cardresearch Cardiologia Assistencial e de Pesquisas Ltda, Belo Horizonte, Estado de Minas Gerais.

Canada

S. Zieroth, St. Boniface General Hospital, Winnipeg, Manitoba; D. Dion, Centre de sante et de services sociaux de Beauce, St. Georges-de-Beauce, Quebec; D. Savard, CSSS Haut-Richelieu-Rouville, St-Jean-sur-Richelieu, Quebec; R. Bourgeois, G.A. Research Associates Ltd/Ltee, Moncton, New Brunswick; C. Constance, Hopital Maisonneuve Rosemont Recherche Clinique Polyclinique, Montreal, Quebec; K. Anderson, Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia; S. Verma, North York Diagnostic and Cardiac Centre, Toronto, Ontario; M. Leblanc, Institut Universitaire de Cardiologie et de Pneumologie de Quebec, Quebec., Quebec; Derek Yung, Heart Health Institute, Scarborough, Ontario; E. Swiggum, Victoria Heart Institute Foundation, Victoria, British Columbia; L. Pliamm, Canadian Phase Onward Inc., Toronto, Ontario; B. Tyrrell, Royal Alexandra Hospital, Edmonton, Alberta; T. Huynh, Montreal General Hospital, Montreal, Quebec; J. Spiegelman, Humber River Hospital, Toronto, Ontario; N. Giannetti, McGill University Health Centre/Glen Site / Royal Victoria Hospital, Montreal, Quebec; J. Lavoie, Centre de Dépistage et Recherche Cardiovasculaire Rive- Sud, Longeuil, Quebec; M. Hartleib, Kawartha Cardiology Clinical Trials, Peterborough, Ontario; R. Bhargava, Heart Care Research, Oshawa, Ontario; L. Straatman, Vancouver General Hospital, Vancouver, British Columbia; S. Virani, Vancouver General Hospital, Vancouver, British Columbia; A. Costa-Vitali, Cardiovascular Contract Research Organization LTD, Sudbury, Ontario; L. Hill, Brampton Cardio Pulmonary Clinic, Brampton, Ontario; M. Heffernan, M Heffernan Medicine Professional Corp., Oakville, Ontario; Yaariv Khaykin, PACE (Partners in Advanced Cardiac Evaluation), Newmarket, Ontario; J. Ricci, Scarborough Cardiology Research, Scarborough, Ontario; A. Zhai, Royal University Hospital, Saskatoon, Saskatchewan; B. Lubelsky, Willowdale, Ontario; M. Toma, St. Paul's Hospital, Vancouver, British Columbia; L. Yao, York, Ontario; L. Noronha, Toronto, Ontario; M. Babapulle, Waterloo, Ontario; A. Pandey, Cambridge Cardiac Care Inc., Cambridge, Ontario; G. Curnew, Curnew Medicine Professional Corporation, Ontario; J. Berlingieri, JBN Medical Diagnostics Services Inc., Burlington, Ontario; S. Kouz, C.H. Reg. de Lanaudiere, St. Charles- Borromeo, Quebec; E. Lonn, Hamilton General Hospital, Hamilton, Ontario; R. Chehayeb, ViaCar Recherche Clinique Inc., Greenfield Park, Quebec.

China

Y. Zheng, The First Hospital of Jilin University, Changchun, Jilin Province; Y. Sun, The First Hospital of China Medical University, Shenyang, Liaoning Province; Z. Fan, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan Province; X. Han, General Hospital of Shenyang Military Region, Shenyang, Liaoning Province; X. Jiang, Renmin Hospital of Wuhan University, Wuhan, Hubei Province; Q. Tang, Renmin Hospital of Wuhan University, Wuhan, Hubei Province; Z. Zheng, Hunan Provincial People's Hospital, Changsha, Hunan Province; J. Zhang, National Center for Cardiovascular diseases China and Fu Wai Hospital, Beijing, Beijing Municipality; Y. Zhang, Cardiovascular Institute and Fu Wai Hospital, Beijing, Beijing Municipality; A. Shen, Beijing Friendship Hospital, Beijing, Beijing Municipality; J. Yu, The No.2 Hospital Affiliated to Lanzhou University, Lanzhou, Gansu Province; J. Ye, Dongguan People's Hospital, Dongguan, Guangdong Province; Y. Yao, The First Affiliated Hospital of Lanzhou University, Lanzhou, Gansu Province; J. Yan, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu Province; X. Xu, The First People Hospital of Yueyang, Yueyang, Hunan Province; J. Ma, Hainan General Hospital, Haikou, Hainan Province; Y. Li, Shanghai Huashan Hospital, Shanghai, Shanghai Municipality; S. Li, Nanchang University Affiliated 3rd Hospital, Nanchang, Jiangxi Province; S. Lu, Haikou People's Hospital, Haikou, Hainan Province; X. Kong, Jiangsu Province Hospital, Nanjing, Jiangsu Province; G. Yang, Yanbian University Hospital, Yanji, Jilin Province; Z. Yao, Tianjin Union Medical Center Nankai University Affiliated Hospital, Tianjin, Tianjin Municipality; Y. Zhang, The Third Hospital of Changsha, Changsha, Hunan Province; Yizhi Pan, Guangzhou First People's Hospital, Guangzhou, Guangdong Province; X. Guo, Tongji Hospital, Wuhan, Hubei Province; Z. Sun, Shengjing Hospital of China Medical University, Shenyang, Liaoning Province; Y. Dong, The First Affiliated Hospital, SUN YAT-SEN University, Guangzhou, Guangdong Province; D. Peng, The Second Xiangya Hospital of Central South University, Changsha, Hunan Province; Z. Yuan, First Affiliated Hospital of Xi'an

JiaoTong University, Xi'an, Shaanxi Province; J. Lin, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian Province.

Czech Republic

O. Jerabek, Kardiologická ambulance s.r.o., Příbram VIII; H. Burianová, Poliklinika Humanitas, Bilovec; T. Fiala, Angiocor s.r.o., Zlín; J. Hubac, MUDr. Jan Hubac, s.r.o. Kardiologická Ambulance, Chrudim; O. Ludka, MUDr. Alexandra Ludková, Brno; Z. Monhart, KIGE s.r.o., Znojmo; P. Vodnanský, PV - kardiologie s.r.o., Pardubice; K. Zeman, Nemocnice ve Frydku- Mistku, příspěvková organizace, Frydek-Místek; D. Foldyna, Internal and Cardiology Practice, Brno; Jiri Krupicka, Medicus Services Ltd, Brandýs nad Labem; Ivo Podpera, Hospital Kladno, Kladno; L. Busak, KardioLouny s.r.o., Louny; M. Radvan, Nemocnice Trebic p.o., Trebic; Z. Vomacka, Zdenek Vomacka, Olomouc; R. Prosecky, Fakultní nemocnice u sv. Anny v Brně, Brno; R. Cifková, Thomayerova nemocnice, Praha 4 – Krč; Vaclav Durdil, Fakultní nemocnice v Motole, Praha; J. Vesely, Edumed s. r. o., Broumov; J. Vaclavik, Kardio Vaclavik s.r.o., Olomouc; P. Cervinka, Masaryk Hospital in Usti n. Labem, Usti nad Labem; A. Linhart, Všeobecná fakultní nemocnice v Praze, Praha; T. Brabec, Vojenská nemocnice Brno, Brno; R. Miklik, Amkardia s.r.o, Brno.

France

E. Bonnefoy Cudraz, Hôpital Louis Pradel - Groupement Hospitalier Est - Hospices Civils de Lyon, Bron; A. Jobbe Duval, Hôpital Cardio- Vasculaire et Pneumologique Louis Pradel - GH Est - Hospices Civils, Bron; D. Tomasevic , Hôpital Cardio- Vasculaire et Pneumologique Louis Pradel - GH Est - Hospices Civils, Bron; G. Habib, Hôpital de la Timone - CHU de Marseille (AP- HM), Marseille; R. Isnard, Hôpital La Pitié Salpêtrière, Paris; F. Picard, Hôpital Haut-Lévêque - Groupe Hospitalier Sud - CHU de Bordeaux, Pessac; P. Khanoyan, Hôpital Saint Joseph, Marseille; J. Dubois- Rande, Hôpital Henri Mondor - AP-HP, Créteil; M. Galinier, Hôpital Rangueil - CHU de Toulouse, Toulouse; F. Roubille, Hôpital Arnaud de Villeneuve - CHU de Montpellier, Montpellier; J. Alexandre, Hôpital de la Côte de Nacre - CHU de Caen, Caen; Dominique Babuty, Hôpital Trousseau - CHRU de Tours, Chambray-lès-Tours; N. Delarche, Centre Hospitalier de Pau, Pau; M. Seronde, Hôpital Jean Minjoz - CHU de Besançon, Besançon; J. Berneau, Hôpital de Bayonne - Centre Hospitalier de la Côte Basque, Bayonne; N. Girerd, Institut Louis Mathieu - CHU de Nancy-Brabois, Vandœuvre-lès- Nancy.

Germany

H. Bourhaial, St. Johannes Hospital, Dortmund; H. Olbrich, Asklepios Klinik Langen-Seligenstadt GmbH, Langen; S. Genth-Zotz, Johannes-Gutenberg- Universität Mainz, Mainz; E. Kemala, Petrus-Krankenhaus, Wuppertal; B. Lemke, Märkische Gesundheitsholding GmbH & Co. KG, Lüdenscheid; M. Böhm, Universitätsklinikum des Saarlandes; Homburg/Saar; S. Schellong, Städtisches Klinikum Dresden-Friedrichstadt, Dresden; W. Rieker, Studienzentrum Rankestrasse, Berlin; M. Faghieh, Studienzentrum Bocholderstraße, Essen; A. Birkenfeld, GW T-TUD GmbH, Dresden; A. Begemann, Asklepios Klinik St. Georg, Hamburg; A. Ghanem, Asklepios Klinik St. Georg, Hamburg; A. Ujeyl, Asklepios Klinik St. Georg, Hamburg; S. von Haehling, Universitätsmedizin Göttingen, Georg-August-Universität, Göttingen; H. Ince, Universitätsmedizin Rostock, Berlin; T. Dorsel, Dr. med. Thomas Dorsel, Warendorf; J. Bauersachs, Medizinische Hochschule Hannover, Hannover; M. Prull, Augusta-Kranken- Anstalt gGmbH, Bochum; H. Darius, Vivantes-Klinikum Neukölln, Berlin; A. Wilke, Kardiologische Praxis Papenburg, Papenburg; J. Sauter, Zentrum für Klinische Forschung, Wangen; U. Rauch- Kroehnert, Charité - Universitätsmedizin Berlin, Berlin; N. Frey, Universitätsklinikum Schleswig-Holstein, Kiel; C. P. Schulze, Universitätsklinikum Jena, Jena; W. König, Deutsches Herzzentrum München, München; L. Maier, Universitätsklinikum Regensburg, Regensburg; F. Menzel, Praxis Dr. Menzel, Dessau-Roßlau; N. Proskynitopoulos, Kardiologische Gemeinschaftspraxis Nienburg, Nienburg; H. Ebert, Kardiologische Gemeinschaftspraxis, Riesa; H.

Sarnighausen, Praxis Oedeme, Lüneburg; H. Düngen, Universitätsklinikum Charité, Berlin; M. Licka, Universitätsklinikum Heidelberg, Heidelberg; N. Marx, Universitätsklinikum Aachen, Aachen; C. Stellbrink, Klinikum Bielefeld Mitte, Bielefeld; B. Winkelmann, ClinPhenomics GmbH & Co. KG, Frankfurt; N. Menck, HELIOS Klinikum Erfurt, Erfurt.

Hungary

L. Koenyves, Lausmed Kft. Outpatient Unit of Internal Medicine, Szent Rokus Hospital, Baja; F. Lakatos, Belgyogyaszati es Kardiologiai Maganrendelo, Bekescsaba; A. Matoltsy, Kanizsai Dorottya Korhaz, Nagykanizsa; E. Noori, Fejer Megyei Szent Gyorgy Egyetemi Oktato Korhaz, Szekesfehervar; P. Andrassy, Bajcsy Hospital, Budapest; S. Kancz, Gottsegen Gyorgy Hungarian Institute of Cardiology, Budapest; G. Simon, Bugat Pal Hospital, Gyongyos; T. Sydo, Veszpremi Sziv es Egeszseg Centrum, Veszprem; A. Vorobcsuk, Da Vinci Maganklinika, Pecs; B. Merkely, Semmelweis University Heart and Vascular Center, Budapest; R. Gabor Kiss, Magyar Honvedseg Egeszsegugyi Kozpont, Kalman Toth, Pecs Tudomanyegyetem, Pécs; I. Szakal, Selye Janos Hospital, Komarom; N. Laszlo Kardiologiai Maganrendeles, Oroshaza; T. Barany, Clinexpert Egeszsegugyi Szolg. es Ker. Kft., Budapest; A. Nagy, Uzsoki Utcai Korhaz, Budapest; E. Szolnoki, Medipulm Bt., Debrecen.

India

V. Chopra, Medanta-The Medicity, Gurgaon, Delhi; V. Rastogi, Fortis Escorts Heart Institute and Research Centre, New Dehi, Delhi; B. Shah, Doctor Jivraj Mehta Smarak Health Foundation, Ahmedabad, Gujarat; A. Mullasari, Madras Medical Mission, Chennai, Tamil Nadu; J. Shankar, Madras Medical Mission, Chennai, Tamil Nadu; V. Mehta, GB Pant Hospital, New Dehi, Delhi; A. Oomman, Apollo Speciality Hospital, Chennai, T. Nadu; Upendra Kaul, Batra Hospital And Research Centre, Delhi, Delhi; S. Komarlu, Narayana Institute of Cardiac Sciences, Bangalore, Karnataka; D. Kahali, B.M. Birla Heart Research Centre, Kolkatta, West Bengal; A. Bhagwat, Kamal Nayan Bajaj Hospital, Aurangabad, Maharashtra; V. Vijan, Vijan Cardiac and Critical Care Centre, Nasik, Maharashtra; N. Kamalakar Ghaisas, Siddhi Hospital, Nasik; A. Mehta, Sir Gangaram Hospital, New Delhi, Delhi; Y. Kothari, Rajarajeswari Medical College, Bengaluru, Karnataka.

Italy

S. Taddei, Azienda Ospedaliero Universitaria Pisana, Pisa, Toscana; M. Scherillo, Azienda Ospedaliera G. Rummo, Benevento, Campania; V. Zacà, A.O.U. Senese Policlinico Santa Maria alle Scotte, Siena, Toscana; S. Genovese, Centro Cardiologico Monzino-IRCCS, Milano, Lombardia; A. Salvioni, Centro Cardiologico Monzino-IRCCS, Milano, Lombardia; A. Fucili, Azienda Ospedaliera Universitaria Arcispedale Sant'Anna, Ferrara, Emilia-Romagna; F. Fedele, Umberto I Pol. di Roma-Università di Roma La Sapienza, Roma, Lazio; F. Cosmi, Ospedale della Val di Chiana Santa Margherita, Cortona, Toscana; M. Volpe, Azienda Ospedaliera Sant'Andrea- Università di Roma La Sapienza, Roma, Lazio; M. Senni, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII), Bergamo, Lombardia; C. Mazzone, Azienda Servizi Sanitari 1 Triestina, Trieste, Friuli-Venezia Giulia; G. Esposito, Azienda Ospedaliera Universitaria "Federico II", Napoli, Campania.

Japan

M. Doi, Kagawa Prefectural Central Hospital, Kagawa, Takamatsu; H. Yamamoto, Yamamoto Clinic, Kanagawa, Sagami-hara; S. Sakagami, National Hospital Organization Kanazawa Medical Center, Ishikawa, Kanazawa; S. Oishi, Hyogo Brain and Heart Center, Hyogo, Himeji; Y. Yasaka, Hyogo Brain and Heart Center, Hyogo, Himeji; H. Tsuboi, Ogaki Municipal Hospital, Gifu, Ogaki; Y. Fujino, New Tokyo Heart Clinic, Chiba, Matsudo; S. Matsuoka, Seikeikai New Tokyo Heart Clinic, Chiba, Matsudo; Y. Watanabe, Seikeikai New Tokyo Heart Clinic, Chiba, Matsudo-shi; T. Himi, Kimitsu

Chuo Hospital, Chiba, Kisarazu; T. Ide, Kyushu University Hospital, Fukuoka, Fukuoka; M. Ichikawa, Higashiosaka City Medical Center, Osaka, Higashiosaka; Y. Kijima, Higashiosaka City Medical Center, Osaka, Higashiosaka; T. Koga, Steel Memorial Yawata Hospital, Fukuoka, Kitakyushu; S. Yuda, Teine Keijinkai Hospital, Hokkaido, Sapporo; K. Fukui, Kanagawa Cardiovascular and Respiratory Center, Kanagawa, Yokohama; T. Kubota, Saiseikai Fukuoka General Hospital, Fukuoka, Fukuoka; M. Manita, Naha City Hospital, Okinawa, Naha; H. Fujinaga, Tokushima Prefectural Central Hospital, Tokushima, Tokushima; T. Matsumura, Kumamoto Rosai Hospital, Kumamoto, Yatsushiro; Y. Fukumoto, Sendai Tokushukai Hospital, Miyagi, Sendai; Y. Kawai, Okayama City General Medical Center, Okayama, Okayama; G. Hiasa, Ehime Prefectural Central Hospital, Ehime, Matsuyama; Y. Kazatani, Ehime Prefectural Central Hospital, Ehime, Matsuyama; M. Mori, Japan Community Health Care Organization Kyushu Hospital, Fukuoka, Kitakyushu; A. Ogimoto, Uwajima City Hospital, Uwajima, Ehime; M. Inoko, Kitano Hospital, Osaka, Osaka; M. Oguri, Kasugai Municipal Hospital, Aichi, Kasugai; M. Kinoshita, Shobara Red Cross Hospital, Shobara-shi; K. Okuhara, Shobara Red Cross Hospital, Hiroshima, Shobara; N. Watanabe, Shobara Red Cross Hospital, Hiroshima, Shobara; Y. Ono, Ome Municipal General Hospital, Tokyo, Ome; K. Otomo, Ome Municipal General Hospital, Tokyo, Ome; Y. Sato, Hyogo Prefectural Amagasaki General Medical Center, Hyogo, Amagasaki; T. Matsunaga, Seiwakai Suizenji Touya Hospital, Kumamoto, Kumamoto; A. Takaishi, Mitoyo General Hospital, Kagawa, Kanonji; N. Miyagi, Jinaikai Urasoe General Hospital, Urasoe-shi; H. Uehara, Urasoe General Hospital, Okinawa, Urasoe; H. Takaishi, Yodogawa Christian Hospital, Osaka, Osaka; Masahiro Yagi, The Cardiovascular Center of Sendai, Miyagi, Sendai; M. Arikawa, Oita Medical Center, Oita, Oita; T. Hashizume, Minami Wakayama Medical Center, Wakayama, Tanabe; T. Koizumi, Mito Medical Center, Ibaraki, Higashiibaraki-gun; K. Nakayama, Mito Medical Center, Ibaraki, Higashiibaraki-gun; S. Taguchi, Mito Medical Center, Ibaraki, Higashiibaraki-gun; M. Nanasato, Japanese Red Cross Nagoya Daini Hospital, Aichi, Nagoya; Y. Yoshida, Japanese Red Cross Nagoya Daini Hospital, Aichi, Nagoya; S. Tsujiyama, JA Hiroshima General Hospital, Hiroshima, Hatsukaichi; T. Nakamura, National Hospital Organization Kyushu Medical Center, Fukuoka, Fukuoka; K. Oku, Nagasaki Medical Center, Nagasaki, Omura; M. Shimizu, National Hospital Organization Kobe Medical Center, Hyogo, Kobe; M. Suwa, Hokusetsu General Hospital, Osaka, Takatsuki; Y. Momiyama, National Hospital Organization Tokyo Medical Center, Tokyo, Meguro-ku; H. Sugiyama, Fukuyama City Hospital, Hiroshima, Fukuyama; K. Kobayashi, Toyota Memorial Hospital, Aichi, Toyota; S. Inoue, Aso Co., Ltd Iizuka Hospital, Fukuoka, Iizuka; T. Kadokami, Fukuokaken Saiseikai Futsukaichi Hospital, Fukuoka, Chikushino; K. Maeno, Fukuiken Saiseikai Hospital, Fukui, Fukui; K. Kawamitsu, Okinawatokushukai Nanbu Tokushukai Hospital, Okinawa, Shimajiri-gun; Y. Maruyama, Kosekai Iwatsuki-minami Hospital, Saitama, Saitama; A. Nakata, San-Ai Hospital, Saitama, Saitama; Y. Shibata, Miyazaki Medical Association Hospital, Miyazaki, Miyazaki; A. Wada, Kusatsu General Hospital, Shiga, Kusatsu; H. Urata, Fukuoka University Chikushi Hospital, Fukuoka, Chikushino; T. Kataoka, Seichokai Bell Land General Hospital, Osaka, Sakai; T. Matsumoto, Sendai Kousei Hospital, Miyagi, Sendai; N. Takahashi, Matsuyama Shimin Hospital, Ehime, Matsuyama; M. Imamaki, Chiba Heart Clinic, Chiba, Chiba; N. Watanabe, Hokushin General Hospital, Nagano, Nakano; T. Yoshitama, Tokyo Rosai Hospital, Tokyo, Ota-ku; T. Saito, Shirakawa Kosei General Hospital, Fukushima, Shirakawa; H. Sekino, Sekino Hospital, Tokyo, Toshima-ku; Y. Furutani, Kanmon Medical Center, Yamaguchi, Shimonoseki; M. Koda, Chuno Kosei Hospital, Gifu, Seki; S. Matsuoka, Uji-Tokushukai Medical Center, Kyoto, Uji; T. Shinozaki, National Hospital Organization Sendai Medical Center, Miyagi, Sendai; K. Hirabayashi, Tomakomai City Hospital, Hokkaido, Tomakomai; R. Tsunoda, Japanese Red Cross Kumamoto Hospital, Kumamoto, Kumamoto; K. Yonezawa, National Hospital Organization Hakodate Hospital, Hokkaido, Hakodate; H. Hori, Nagoya Kyoritsu Hospital, Aichi, Nagoya.

Mexico

G. Llamas Esperon, Hospital Cardiológica Aguascalientes, Aguascalientes, Aguascalientes; J. Illescas Díaz, Unidad de Investigación Clínica, Guadalajara, Jalisco – Guadalajara; P. Fajardo

Campos, Centro de Investigacion Cardiovascular y Metabolica, Tijuana; J. Almeida Alvarado, Centro Integral Medico SJR S.C., San Juan del Rio, Querétaro – Querétaro; A. Bazzoni Ruiz, Centro de Investigacion Alberto Bazzoni S.A. de C.V., Torreon, Coahuila – Saltillo; I. Lopez Alcocer, Hospital Universitario Dr Jose Eleuterio Gonzalez, Monterrey, Nuevo León – Monterrey; Leobardo Valle Molina, Centro de Investigacion Clinica Acelerada, S.C., Mexico, Ciudad de México; C. Hernandez Herrera, Instituto Cardiovascular de Monclova, S de RL de CV, Monclova, Coahuila – Saltillo; C. Calvo Vargas, Diseño y Planeación en Investigacion Medica S.C., Guadalajara, Jalisco – Guadalajara; F. G. Padilla Padilla, Cardiologia Clinica Intervencionista, Guadalajara, Jalisco – Guadalajara; I. Rodriguez Briones, Cardioarritmias e Investigación SC, San Luis Potosi; E. Chuquiure Valenzuela, Instituto Nacional de Cardiologia Ignacio Chavez, Distrito Federal, Ciudad de México; M. Aguilera Real, Centro de Investigacion Biomedica y Farmaceutica, S.C., Mexico, J. Carrillo Calvillo, Hospital Central "Dr. Ignacio Morones Prieto", San Luis Potosi; M. Alpizar Salaza , C. Esp. en Diabetes, Obesidad y Prevención de Enf. Cardiovasculares, S.C. (CEDOPEC, S.C), México, Ciudad de México; J. Cervantes Escárcega , C. Esp. en Diabetes, Obesidad y Prevención de Enf. Cardiovasculares, S.C. (CEDOPEC, S.C), México, Ciudad de México; R. Velasco Sanchez, Hospital Dr. ngel Leaño, Guadalajara, Jalisco – Guadalajara.

Netherlands

N. Al – Windy, Gelre Ziekenhuizen locatie Zutphen, ZUTPHEN; L. van Heerebeek, Onze Lieve Vrouwe Gasthuis, Amsterdam; L. Bellersen, Radboud Universitair Medisch Centrum, Nijmegen; H. Brunner- La Rocca, Maastricht Universitair Medisch Centrum, MAASTRICHT; J. Post, Catharina Ziekenhuis, EINDHOVEN; G.C.M. Linssen, ZGT Almelo, ALMELO; M. van de Wetering, BovenIJ Ziekenhuis, AMSTERDAM; R. Peters , Tergooiziekenhuizen locatie Blaricum, BLARICUM; R. van Stralen , Tergooiziekenhuizen locatie Blaricum, Blaricum; R. Groutars, Onze Lieve Vrouwe Gasthuis, Locatie West, Amsterdam; P. Smits, Maasstad Ziekenhuis, Rotterdam; A. Yilmaz, Maasstad Ziekenhuis, ROTTERDAM; W. E.M. Kok, Amsterdam UMC, Locatie AMC, Amsterdam; P. Van der Meer, Universitair Medisch Centrum Groningen, Groningen; P. Dijkmans, Zaans Medisch Centrum, ZAANDAM; R. Troquay, Vie Curi Medisch Centrum, VENLO; A. Pauline van Alem, HMC Bronovo, Den Haag; R. Van de Wal, Bernhoven Uden, UDEN; L. Handoko, Amsterdam UMC, location VUMC, AMSTERDAM; I.C.D. Westendorp, Rode Kruis Ziekenhuis Beverwijk, BEVERWIJK; P.F.M.M. van Bergen, Vasculair Onderzoek Centrum, HOORN; B. J.W.M. Rensing, St. Antonius Ziekenhuis, Nieuwegein; P. Hoogslag, Diaconessenhuis Meppel, Meppel; B. Kietselaer, Zuyderland Medisch Centrum – Heerlen, Heerlen; J. A. Kragten, Zuyderland Medisch Centrum, HEERLEN; F. R. den Hartog, Ziekenhuis Gelderse Vallei, EDE; Antonio Alings, Amphia Ziekenhuis, Breda.

Poland

L. Danilowicz- Szymanowicz, University Clinical Center, Gdansk; G. Raczak, University Clinical Center, Gdansk; W. Piesiewicz, ETG Lodz, Lodz; W. Zmuda, Medicome Sp. z o.o., Oswiecim; W. Kus, Individual Specialized Practice, Lodz; P. Podolec, Krakow Specialistic Hospital of John Paul II, Krakow; W. Musial, University Clinic Hospital in Bialystok, Bialystok; G. Drelich, Centermed Lublin, Lublin; G. Kania, ETG Skierniewice, Skierniewice; P. Miekus, NZOZ Pro-Cordis Sopockie, Gdynia; S. Mazur, Centrum Medyczne Medyk, Rzeszow; A. Janik, KO-MED Centra Kliniczne Staszow, Staszow; J. Spyra, Janusz Pyra Specjalistyczna Praktyka Lekarska, Ruda Slaska; J. Peruga, NZOZ SALUS, Lodz; P. Balsam, Samodzielny Publiczny Centralny Szpital Kliniczny, Warsaw; B. Krakowiak, 4 Military Clin. Hosp. Centre of Heart Diseases, Wroclaw; J. Szachniewicz, 4th Military Clinical Hospital with polyclinic - SP ZOZ, Wroclaw; M. Ginel, KLIMED Marek Klimkiewicz, Bialystok; J. Grzybowski, Instytut Kardiologii, Warsaw; Witold Chrustowski, Lowickie Cardiology Center, Lowicz; P. Wojewoda, Lowickie Cardiology Center, Lowicz; A. Kalinka, Polsko-Amerykanske Kliniki Serca, Chorzow; A. Zurakowski, Polsko-Amerykanske Kliniki Serca., Chrzanow; R. Koc, ClinicMed Badurski i wspolnicy Spolka Jawna, Bialystok; M. Debinski, American Heart of Poland Sp. z o.o., Dabrowa Gornicza; W. Fil, American Heart of Poland Sp. z o.o., Bielsko-Biala; M. Kujawiak, Lukmed

Lukasz Wozniak, Siedlce; J. Forys, Zgierskie Center of Cardiology MED-PRO, Zgierz; M. Kasprzak, NZOZ Centrum Medyczne KERmed, Bydgoszcz; M. Krol, American Heart of Poland Sp. z o.o., Ustron; P. Michalski, Specialist Hospital J. Dietla NZOZ Specialized Clinic "Gemini", Zychlin; E. Mirek-Bryniarska, Specialist Doctor Ewa Mirek-Bryniarska, Krakow; Kazimierz Radwan, American Heart of Poland Sp. z o.o., Tychy; G. Skonieczny, The Provincial Polyclinical Hospital in Torun, Torun; K. Stania, American Heart of Poland Sp. z o.o., Nysa; G. Skoczylas, ETG Warszawa, Warszawa; A. Madej, Szpital Zakonu Bonifratow Sp. z o.o., Katowice; J. Jurowiecki, Poradnia Kardiologiczna Jaroslaw Jurowiecki, Gdansk; B. Firek, NZOZ HEUREKA, Piaseczno; B. Wozakowska-Kaplon; Regional Hospital in Kielce Swietokrzyskie Center of Cardiology, Kielce; K. Cymerman, Indywidualna Specjalistyczna Praktyka Lekarska w Dziedzinie Kardiologii Lek.

Republic of Korea

H. Cho, Seoul National University Hospital, Seoul; J. Oh Na, Korea University Guro Hospital, Seoul; B. Yoo, Wonju Severance Christian Hospital, Wonju; J. Choi, Samsung Medical Center, Seoul; J. Shin, Ajou University Hospital, Suwon; M. Cho, Chungbuk National University Hospital, Cheongju; D. Choi, Seoul National University Bundang Hospital, Seongnam; S. Hwan Han, Gachon University Gil Medical Center, Incheon; J. Jeong, Chungnam National University Hospital, Daejeon; J. Kim, Asan Medical Center, Seoul; S. Min Kang, Severance Hospital, Seoul; D. Kim, Inje University Busan Paik Hospital, Busan; M. Hyun Kim, Dong-A University Hospital, Busan

Spain

J. López- Sendón, Hospital Universitario La Paz, Madrid, Madrid; L. de la Fuente Galán, Hospital Clínico Universitario de Valladolid, Valladolid, Valladolid; J. Delgado Jiménez, Hospital Universitario 12 de Octubre, Madrid, Lugo; N. Manito Lorite, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona; M. Pérez de Juan Romero, Complejo Hospitalario Universitario de Orense, Orense, Ourense; F. Cereto Castro, Hospital Quiron Barcelona, Barcelona, Barcelona; J. González Juanatey, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, La Coruna; J. Gómez, Hospital Clínico Universitario Virgen de la Victoria, Málaga, Malaga; M. Sanmartín Fernández, Hospital Ramón y Cajal, Madrid, Madrid; X. Garcia-Moll Marimon, Hospital de la Santa Creu i Sant Pau, Barcelona, Barcelona; D. Pascual Figal, Hospital Universitario Virgen de la Arrixaca, El Palmar, Murcia; R. Bover Freire, Hospital Clínico San Carlos, Madrid; Madrid,

United Kingdom

M. Saxena, St Bartholomew's Hospital, London; Z. Yousef, University Hospital of Wales, Cardiff; C. Clifford, Wycombe General Hospital, High Wycombe; Christopher Arden, Park & St Francis Surgery, Eastleigh; A. Bakhai, Barnet General Hospital, Barnet; I. Squire, Glenfield Hospital, Leicester; G. Jenkins, Morriston Hospital, Swansea; C. Travill, Luton and Dunstable University Hospital, Luton; Dallas Price, St Mary's Hospital, Newport

United States

J. Neutel, Orange County Research Center, Tustin, California; K. Adams, University of North Carolina Chapel Hill, Chapel Hill, North Carolina; P. Balfour, Cardiology Consultants, Inc, Pensacola, Florida; A. Djamson, Metropolitan Cardiovascular Consultants, Beltsville, Maryland; P. Duncan, Cardiac Health Management Network, P.C., Chester, Virginia; M. Hong, Trinity Medical WNY-PC, Cheektowaga, New York; S. Woodhouse, Cardiovascular Group PC, Lawrenceville, Georgia; R. MacNevin, Palmetto Health, Columbia, South Carolina; B. Rama, Rama Research LLC, Marion, Ohio; K. Anderson, Marshfield Clinic, Marshfield, Wisconsin; C. Broome- Webster, Avail Clinical Research, Deland, Florida; S. Kindsvater, Baylor Scott & White The Heart Hospital Plano, Plano, Texas; M. Baretella, Peninsula Research, Inc., Ormond Beach, Florida; S. Pinney, Mount Sinai School of Medicine, New York, New York; A. Cohen, Aurora Denver Cardiology Associates, Aurora,

Colorado; K. Vora, Research Integrity, LLC, Owensboro, Kentucky; K. Challappa, Krishnan Challappa M.D. PSC, Elizabeth, Kentucky; S. West, Alpine Research Organization, Farmington, Utah; S. Baum, Integrated Heart Care, Boca Raton, Florida; J. Cox, Covigilant Research, LLC, Riverside, California; S. Jani, MedStar Health Research Institute, Baltimore, Maryland; A. Karim, AngioCardiac Care of Texas, Houston, Texas; A. Akhtar, BI Research Center, Houston, Texas; R. Goldberg, La Mesa Cardiac Center, La Mesa, California; Z. Bhatti, Columbus Regional Research Institute, Columbus, Georgia; M. Budoff, Los Angeles Biomedical Research Institute, Torrance, California; E. Bush, East Mountain Medical Associates, PC, Great Barrington, Massachusetts; A. Potler, East Mountain Medical Associates, PC, Great Barrington, Massachusetts; B. Ellis, Houston Methodist Reserach Institute – AOCT, Houston, Texas; J. Dy, Clinical Trials of America, Inc., Lenoir, North Carolina; J. Fialkow, Cardiovascular Research Center of South Florida, Miami, Florida; R. Sangrigoli, Doylestown Health Cardiology, a division of Doylestown Health Physicians, Doylestown, Pennsylvania; K. Ferdinand, Tulane University Heart & Vascular Institute, New Orleans, Louisiana; C. East, Soltero Cardiovascular Research Center, Dallas, Texas; S. Falkowski, Southeast Clinical Research, LLC, Chiefland, Florida; S. Donahoe, Northwell Health Physician Partners Cardiology, Riverhead, New York; R. Ebrahimi, VA Greater Los Angeles Healthcare System, Los Angeles, California; G. Kline, University of North Texas Health Science Center, Fort Worth, Texas; B. Harris, Integrative Research Associates, Fort Lauderdale, Florida; R. Khouzam, Methodist Hospital, Memphis, Tennessee; N. Jaffrani, Cambridge Medical Trials, Alexandria, Louisiana; N. Jarmukli, Salem Veterans Administration Medical Center, Salem, Virginia; N. Kazemi, Palm Research Center, Inc., Las Vegas, Nevada; M. Koren, Jacksonville Center for Clinical Research, Jacksonville, Florida; K. Friedman, Johns Hopkins University Hospital School of Medicine, Baltimore, Maryland; W. Herzog, Johns Hopkins University Hospital School of Medicine, Baltimore, Maryland; D. Cheung, Long Beach Center for Clinical Research, Long Beach, California; M. Grover-McKay, Long Beach Center for Clinical Research, Long Beach, California; P. Hauptman, Saint Louis University, Saint Louis, Missouri; D. Mikhalkova, Saint Louis University, St. Louis, Missouri; S. Khouri, University of Toledo, Toledo, Ohio; F. McGrew, Stern Cardiovascular Foundation, Inc., Germantown, Tennessee; P. McCullough, Baylor Heart & Vascular Hospital, Dallas, Texas; Ronald Littlefield, Palmetto Research Center, LLC, Spartanburg, South Carolina; P. Bradley, Meridian Clinical Research, LLC, Savannah, Georgia; Brent McLaurin, AnMed Health Clinical Research, Anderson, South Carolina; S. Lupovitch, Northwest Heart Clinical Research, LLC, Arlington Heights, Illinois; I. Labin, Indiana Heart Physicians, Indianapolis, Indiana; V. Rao, Franciscan Health Network, Indianapolis, Indiana; M. Leithe, Duke University, Durham, North Carolina; N. Lewis, Hunter Holmes McGuire Veterans Administration Medical Center, Richmond, Virginia; D. Lombardo, University of California at Irvine Medical Center, Orange, California; S. Mahal, Advanced Heart Care, LLC, Bridgewater, New Jersey; V. Malhotra, MultiCare Health System Institute for Research and Innovation, Tacoma, Washington; V. Mehta, Midwest Cardiovascular Research and Education Foundation, Elkhart, Indiana; I. Dauber, South Denver Cardiology Associates PC, Littleton, Colorado; A. Banerjee, Clinical Research of Gastonia, Gastonia, North Carolina; J. Needell, Clinical Research of Gastonia, Gastonia, North Carolina; G. Miller, Cardiology Consultants of Danville, Inc, Danville, Virginia; L. Paladino, Kings County Hospital Center, Brooklyn, New York; Kirubakaran Munuswamy, Holy Cross Hospital Inc., Fort Lauderdale, Florida; M. Nanna, Cardiac Center & Vascular Medicine PLLC, Bronx, New York; E. McMillan, Novant Health Heart & Vascular Institute, Charlotte, North Carolina; M. Mumma, Sarasota Memorial Hospital, Sarasota, Florida; M. Napoli, Clinical Trials of America LA, LLC, Monroe, Louisiana; W. Nelson, Regions Hospital, St. Paul, Minnesota; T. O'Brien, Ralph H. Johnson VA Medical Center, Charleston, South Carolina; A. Adlakha, Clinical Research of Rock Hill, Rock Hill, North Carolina; A. Onwuanyi, Grady Clinical Research Center, Atlanta, Georgia; H. Serota, St. Louis Heart and Vascular, P.C., St. Louis, Missouri; J. Schmedtje, Roanoke Heart Institute PLC, Roanoke, Virginia; A. Paraschos, Kernodle Clinic, Inc., Burlington, North Carolina; R. Potu, Nature Coast Clinical Research, Crystal River, Florida; C. Sai-Sudhakar, Baylor Scott and White Healthcare, Temple, Texas; A. Sauer, University of Kansas Medical Center Research Institute, Inc., Kansas City, Kansas; P. Shah, Capital Cardiology Associates, PC, Albany, New York; H. Skopicki, Stony Brook University Hospital, Stony Brook, New York; H. Bui, Blue Coast Cardiology, Vista,

California; K. Carr, Blue Coast Cardiology, Vista, California; G. Stevens, Shore University Hospital, Manhasset, New York; N. Tahirkheli, South Oklahoma Heart Research Group, Oklahoma City, Oklahoma; J. Tallaj, University of Alabama, Birmingham, Alabama; K. Yousuf, Spectrum Clinical Research, Inc., Towson, Maryland; B. Trichon, Asheville, Cardiology Associates, Asheville, North Carolina; J. Welker, Anne Arundel Health System, Annapolis, Maryland; A. Vest, Tufts Medical Center, Boston, Massachusetts; X. Wang, Rockford Cardiovascular Associates, Rockford, Illinois; R. Abadier, Nature Coast Clinical Research, LLC, PA, Inverness, Florida; S. Dunlap, Augusta University, Augusta, Georgia; N. Weintraub, Augusta University, Augusta, Georgia; A. Malik, York Hospital, York, Pennsylvania; P. Kotha, Purushotham, Akther & Roshan Kotha, MD Inc., La Mesa, California; V. Zaha, University of Texas Southwestern Medical Center, Dallas, Texas; G. Kim, University of Chicago Medicine, Chicago, Illinois; N. Uriel University of Chicago Medicine, Chicago, Illinois; T. Greene, East Coast Institute for Research, LLC, Jacksonville, Florida; A. Salacata, Alpena General Hospital, Alpena, Michigan; R. Arora, North Chicago V.A. Medical Center, North Chicago, Illinois; R. Gazmuri, Captain James A. Lovell Federal Health Care Center, North Chicago, Illinois; J. Kobayashi, Beacon Medical Group, South Bend, Indiana; B. Iteld, Louisiana Heart Center, Covington, Louisiana; R. Dab, Reid Hospital, Richmond, Indiana; Z. Mirza, Reid Hospital, Richmond, Indiana; V. Marques, AdventHealth - Tampa, Tampa, Florida; M. Nallasivan, Merced Vein and Vascular Center; Merced, California; H. Saint-Jacques, Harlem Cardiology on Madison Avenue, New York, New York; K. Barringhaus, WJB Dorne VA Medical Center, Columbia, South Carolina; J. Contreras, Mount Sinai – PRIME, New York, New York; A. Gupta, Orlando Health, Inc. Orlando, Florida; S. Koneru, Orlando Health, Inc., Orlando, Florida; V. Nguyen, Morton Plant Mease Health Care, Inc., Clearwater, Florida

KEY INCLUSION AND EXCLUSION CRITERIA

Inclusion criteria

1. Age \geq 18 years at screening. For Japan only: Age \geq 20 years at screening
2. Men or women. A woman is considered of childbearing potential must be ready and able to use highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria is provided in the patient information
3. Patients with chronic heart failure diagnosed for at least 3 months before Visit 1, and currently in NYHA functional class II, III or IV
4. Chronic heart failure with a reduced left ventricular ejection fraction (LVEF), defined as $LVEF \leq 40\%$ per local reading (obtained under stable conditions by echocardiography, radionuclide ventriculography, invasive angiography, MRI or CT). A historical LVEF may be used if it was measured within 6 months prior to visit 1 or the LVEF may be measured after study consent has been obtained. The LVEF must be documented in an official report prior to randomization
5. In addition to $LVEF \leq 40\%$, patients must have at least one of the following :
 - a) If $EF \geq 36\%$ to $\leq 40\%$: elevated NT-proBNP at Visit 1 ≥ 2500 pg/ml for patients without AF, OR ≥ 5000 pg/ml for patients with AF, analyzed at the Central Laboratory,
 - b) If $EF \geq 31\%$ to $\leq 35\%$: elevated NT-proBNP at Visit 1 ≥ 1000 pg/ml for patients without AF, OR ≥ 2000 pg/ml for patients with AF, analyzed at the Central Laboratory,
 - c) If $EF \leq 30\%$: elevated NT-proBNP at Visit 1 ≥ 600 pg/ml for patients without AF, OR ≥ 1200 pg/ml for patients with AF, analyzed at the Central Laboratory
 - d) For $EF \leq 40\%$ and documented hospitalization for heart failure within 12 months prior to visit 1, elevated NT-proBNP at Visit 1 ≥ 600 pg/ml for patients without AF and ≥ 1200 pg/ml for patients with AF, analyzed at the Central Laboratory.
6. Appropriate dose of medical therapy for heart failure (such as ACEi, ARB, β -blocker, oral diuretics, MRA, ARNI, ivabradine) consistent with prevailing local and international guidelines, stable for at least 1 week prior to Visit 1 (screening visit) and during screening period until Visit 2 (randomization visit). The dose of diuretics must be stable for one week prior to Visit 2. The investigator must document the reason why patient is not receiving target doses per local guidelines
7. Appropriate use of medical devices such as cardioverter defibrillator (ICD) or a cardiac resynchronization therapy (CRT) consistent with prevailing local or international guidelines (refer also to exclusion #29)
8. Body mass index (BMI) < 45 kg/m² at Visit 1 (screening)
9. Signed and dated written ICF (informed consent) in accordance with Good Clinical Practice (GCP) and local regulations, prior to admission to the trial

Exclusion criteria

Cardiovascular diseases or treatments that increase the unpredictability of or change the patients' clinical course, independent of heart failure

- Myocardial infarction (increase in cardiac enzymes in combination with symptoms of ischemia or new ischemic ECG changes), coronary artery bypass graft surgery, or other major cardiovascular surgery, stroke or transient ischemic attack in past 90 days
- Heart transplant recipient or listed for heart transplant. Currently implanted left ventricular assist device
- Cardiomyopathy based on infiltrative diseases (e.g. amyloidosis), accumulation diseases (e.g. haemochromatosis, Fabry disease), muscular dystrophies, cardiomyopathy with reversible causes (e.g. stress cardiomyopathy), hypertrophic obstructive cardiomyopathy, or known pericardial constriction
- Diagnosis of peripartum cardiomyopathy or cardiomyopathy induced by chemotherapy within 12 months
- Any severe (obstructive or regurgitant) valvular heart disease expected to lead to surgery during the trial period
- Acute decompensated heart failure requiring intravenous diuretics, vasodilators, inotropic agents or mechanical support within 1 week of screening and during the screening period prior to randomization
- ICD or cardiac resynchronization therapy within 3 months prior to screening or if there is an intent to implant either device for 3 months following screening

Untreated or undertreated cardiovascular conditions that might influence the course of heart failure or tolerability of the study medications

- Atrial fibrillation or atrial flutter with a resting heart rate >110 bpm, documented by ECG at screening
- Untreated ventricular arrhythmia with syncope in a patient without an ICD within 3 months prior to screening
- Symptomatic bradycardia or second- or third-degree heart block without a pacemaker after adjustment of beta-blocker therapy, if appropriate
- Systolic blood pressure ≥ 180 mmHg at randomization. If systolic blood pressure is 151–179 mmHg, the patient should be receiving ≥ 3 anti-hypertensive drugs
- Symptomatic hypotension and/or a systolic blood pressure <100 mmHg at screening or at randomization

Significant co-morbid conditions that might influence the clinical course, independent of heart failure

- Chronic pulmonary disease requiring home oxygen, oral corticosteroid therapy or hospitalization for exacerbation within 12 months; significant chronic pulmonary disease; or primary pulmonary arterial hypertension
- Acute or chronic liver disease, defined by serum levels of transaminases or alkaline phosphatase more than three times the upper limit of normal at screening
- Impaired renal function, defined as eGFR <20 mL/min/1.73m² (CKD-EPI) or requiring dialysis at the time of screening
- Hemoglobin <9 g/dL at screening
- Major surgery (major according to the investigator's assessment) performed within 90 days prior to screening, or major scheduled elective surgery (e.g. hip replacement) within 90 days after screening
- Gastrointestinal surgery or gastrointestinal disorder that could interfere with trial medication absorption
- Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix, or low risk prostate cancer (patients with pre-treatment PSA<10 ng/mL, and biopsy Gleason score of ≤6 and clinical stage T1c or T2a)
- Presence of any other disease than heart failure with a life expectancy of <1 year (in the opinion of the investigator)

Any condition that might jeopardize patient safety, limit the patients' participation in the trial, or undermine the interpretation of trial data

- Current use or prior use of a SGLT2 inhibitor or combined inhibitor of SGLT1 and SGLT2 within 12 weeks prior to screening or randomization.
- Discontinuation of a SGLT2 inhibitor or combined inhibitor of SGLT1 and SGLT2 inhibitor for the purposes of study enrolment is not permitted
- Known allergy or hypersensitivity to any SGLT2 inhibitors
- History of ketoacidosis
- Patients who must or wish to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial
- Currently enrolled in another investigational device or drug study or are less than 30 days since the completion of a trial of another investigational device or drug study. Any patient receiving any investigational treatment other than the study medications for this trial

- Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, will make the patient unlikely to fulfil the trial requirements or complete the trial
- Women who are pregnant or are nursing or who plan to become pregnant while in the trial
- Any other clinical condition that would jeopardize patient safety while participating in this trial or may prevent the subject from adhering to the trial protocol

MAJOR PROTOCOL-SPECIFIED EFFICACY ENDPOINTS

Primary endpoint

The composite of time to first event of adjudicated cardiovascular death or adjudicated hospitalization for heart failure

The individual components of the primary endpoints, i.e., time to first hospitalization for heart failure and time to cardiovascular death

Secondary endpoints included in hierarchical testing

1. Total (first and recurrent) adjudicated hospitalizations for heart failure
2. Slope of estimated glomerular filtration rate (GFR)

Other prespecified endpoints not included in hierarchical testing

Other secondary endpoints (not included in testing hierarchy) are the following:

1. Composite renal endpoint, defined as time to first occurrence of (1) chronic dialysis; (2) renal transplantation; (3) sustained reduction of $\geq 40\%$ in estimated GFR; or (4) sustained estimated GFR < 15 mL/min/1.73 m² for patients with baseline estimated GFR ≥ 30 mL/min/1.73 m² or < 10 mL/min/1.73 m² for patients with baseline eGFR < 20 mL/min/1.73 m²

Dialysis is regarded as chronic if the frequency of dialysis is twice or more per week for at least 90 days. An estimated reduction in GFR is considered sustained, if it is determined by two or more consecutive post-baseline central laboratory measurements separated by at least 30 days
2. Change from baseline in clinical summary score (heart failure symptoms and physical limitations domains) of the Kansas City Cardiomyopathy Questionnaire (KCCQ) at week 52
3. Total (first and recurrent) hospitalizations for any reason
4. Time to all-cause mortality
5. Time to onset of diabetes (defined as HbA1c $\geq 6.5\%$ or as diagnosed by the investigator) in patients with prediabetes (defined as no history of diabetes, no prior HbA1c ≥ 6.5 , and a pre-treatment HbA1c of ≥ 5.7 and < 6.5)

ADJUDICATED OUTCOME EVENT DEFINITIONS

All cardiovascular endpoint definitions were modifications based on draft recommendations for CDISC August 20, 2014 (Standardized Definitions for Cardiovascular and Stroke Endpoint Events in Clinical Trials for CDISC, Hicks KA et al August 2014) and included in the Clinical Endpoint Committee(CEC) Charter. The CEC Charter specified that in the case of limited or missing data, the committee was to adjudicate events based on their clinical expertise and the totality of the evidence.

Hospitalization for heart failure

A Heart failure hospitalization should include the following criteria:

- 1) The adjudicated primary diagnosis is admission to hospital for heart failure.
 - 2) The patient's length-of-stay in hospital extends for at least 12 hours (or a change in calendar date if the hospital admission and discharge times are unavailable). Emergency room visit for ≥ 12 hours with intravenous therapy would be considered equivalent as admission to hospital.
 - 3) The patient exhibits documented new or worsening symptoms due to HF on presentation, including at least ONE of the following:
 - a. Dyspnea (dyspnea with exertion, dyspnea at rest, orthopnea, paroxysmal dyspnea)
 - b. Decreased exercise tolerance
 - c. Fatigue
 - d. Other symptoms of worsened end-organ perfusion such as dizziness, mental confusion or volume overload such as weight gain or lower extremity swelling.
 - 4) The patient has objective evidence of new or worsening heart failure, consisting of at least TWO physical examination findings OR one physical examination finding and at least ONE laboratory criterion), including:
 - a. Physical examination findings considered to be due to heart failure, including new or worsened:
 - i. Peripheral edema
 - ii. Increasing abdominal distention or ascites (in the absence of primary hepatic disease)
 - iii. Pulmonary rales/crackles/crepitations
 - iv. Increased jugular venous pressure and/or hepatojugular reflux
 - v. S3 gallop
 - vi. Clinically significant or rapid weight gain thought to be related to fluid retention
 - b. Laboratory evidence of new or worsening HF, if obtained within 24 hours of presentation, including:
 - c. Increased B-type natriuretic peptide (BNP)/ N-terminal pro-BNP (NT proBNP) concentrations consistent with decompensation of heart failure. In patients with chronically elevated natriuretic peptides, a significant increase should be noted above baseline.
 - d. Radiological evidence of pulmonary congestion
 - e. Non-invasive diagnostic evidence of clinically significant elevated left- or right-sided ventricular filling pressure or low cardiac output. For example, echocardiographic criteria could include: $E/e' > 15$ or D-dominant pulmonary venous inflow pattern, plethoric inferior vena cava with minimal collapse on inspiration, or decreased left ventricular outflow tract (LVOT) minute stroke distance (time velocity integral (TVI))
- OR**

- f. Invasive diagnostic evidence with right heart catheterization showing a pulmonary capillary wedge pressure (pulmonary artery occlusion pressure) \geq 18 mmHg, central venous pressure \geq 12 mmHg, or a cardiac index $<$ 2.2 L/min/m²
- 5) The patient receives initiation or intensification of treatment specifically for heart failure, including at least ONE of the following:
- a. Augmentation in oral diuretic therapy. NOTE: If the intensification is solely oral diuretics, the duration of hospitalization must be at least 24 hours.
 - b. Intravenous diuretic or vasoactive agent (e.g., inotrope, vasopressor, or vasodilator)
 - c. Mechanical or surgical intervention, including:
 - i. Mechanical circulatory support (e.g., intra-aortic balloon pump, ventricular assist device, extracorporeal membrane oxygenation, total artificial heart)
 - ii. Mechanical fluid removal (e.g., ultrafiltration, hemofiltration, dialysis).

An endpoint heart failure hospitalization requires admission to the hospital for heart failure, worsening of symptoms of heart failure, a duration of hospitalization of at least 12 hours, the intensification of heart failure therapy, and a committee consensus that the hospitalization was primarily due to worsening heart failure. Changes in physical signs or laboratory tests, whenever available and documented, will be considered to be supportive.

Cause of death

Cause of death was adjudicated, as either Cardiovascular death or Non-Cardiovascular death. Cause of death was further categorized when possible.

Cardiovascular death includes the following categories:

1. Death due to Acute Myocardial Infarction: refers to a death by any cardiovascular mechanism (e.g., arrhythmia, sudden death, heart failure, stroke, pulmonary embolus, peripheral arterial disease) \leq 30 days after a MI related to the immediate consequences of the MI, such as progressive heart failure or recalcitrant arrhythmia. We note that there may be assessable mechanisms of cardiovascular death during this time period, but for simplicity, if the cardiovascular death occurs \leq 30 days of the myocardial infarction, it will be considered a death due to myocardial infarction. Acute MI should be verified to the extent possible by the diagnostic criteria outlined for acute MI or by autopsy findings showing recent MI or recent coronary thrombosis.

Death resulting from a procedure to treat a MI (percutaneous coronary intervention (PCI), coronary artery bypass graft surgery (CABG)), or to treat a complication resulting from MI, should also be considered death due to acute MI.

Death resulting from an elective coronary procedure to treat myocardial ischemia (i.e. chronic stable angina) or death due to a MI that occurs as a direct consequence of a CV investigation/procedure/operation should be considered as a death due to a CV procedure.

2. Sudden cardiac death refers to a death that occurs unexpectedly, not following an acute MI, and includes the following deaths:

- a. Death witnessed and occurring without new or worsening symptoms
- b. Death witnessed within 60 minutes of the onset of new or worsening cardiac symptoms, unless the symptoms suggest acute MI
- c. Death witnessed and attributed to an identified arrhythmia (e.g., captured on an electrocardiographic (ECG) recording, witnessed on a monitor, or unwitnessed but found on implantable cardioverter-defibrillator review)

- d. Death after unsuccessful resuscitation from cardiac arrest (e.g., implantable cardioverter defibrillator (ICD) unresponsive sudden cardiac death, pulseless electrical activity arrest)
- e. Death after successful resuscitation from cardiac arrest and without identification of a specific cardiac or non-cardiac etiology
- f. Unwitnessed death in a subject seen alive and clinically stable \leq 72 hours prior to being found dead without any evidence supporting a specific non-cardiovascular cause of death (information regarding the patient's clinical status preceding death should be provided, if available)

Unless additional information suggests an alternate specific cause of death (e.g., Death due to Other Cardiovascular Causes), if a patient is noted to be alive \leq 72 hours of being found dead, sudden cardiac death (criterion 2f) should be recorded. For patients who were not observed alive within 72 hours of death, undetermined cause of death should be recorded (e.g., a subject found dead in bed, but who had not been seen by family for several days).

3. Death due to Heart Failure refers to a death in association with clinically worsening symptoms and/or signs of heart failure regardless of HF etiology. Deaths due to heart failure can have various etiologies, including single or recurrent myocardial infarctions, ischemic or non-ischemic cardiomyopathy, hypertension, or valvular disease.

New or worsening signs and/or symptoms of congestive heart failure (CHF) may include any of the following:

- New or increasing symptoms and/or signs of heart failure requiring the initiation of, or an increase in, treatment directed at heart failure or occurring in a patient already receiving maximal therapy for heart failure
- Heart failure symptoms or signs requiring continuous intravenous therapy or oxygen administration
- Confinement to bed predominantly due to heart failure symptoms
- Pulmonary edema sufficient to cause tachypnea and distress not occurring in the context of an acute myocardial infarction or as the consequence of a primary event
- Cardiogenic shock, manifest as clinical signs and symptoms of hypoperfusion felt to be secondary to cardiac dysfunction, and not occurring in the context of an acute myocardial infarction or as the consequence of a primary arrhythmic event
- Patients who are hospitalized and are being actively treated for heart failure and who have a sudden death as the terminal event will be classified as having a heart failure related death.

4. Death due to Stroke refers to death after a stroke that is either a direct consequence of the stroke or a complication of the stroke. Acute stroke should be verified to the extent possible by the diagnostic criteria outlined for stroke.

5. Death due to Cardiovascular Procedures refers to death caused by the immediate complications of a cardiac procedure.

6. Death due to Cardiovascular Hemorrhage refers to death related to hemorrhage such as a non-stroke intracranial hemorrhage, non-procedural or non-traumatic vascular rupture (e.g., aortic aneurysm), or hemorrhage causing cardiac tamponade.

7. Death due to Other Cardiovascular Causes refers to a CV death not included in the above categories but with a specific, known cause (e.g., pulmonary embolism or peripheral arterial disease).

Non-cardiovascular death is defined as any death with a specific cause that is not thought to be cardiovascular in nature.

The following is a suggested list of non-CV causes of death:

- Pulmonary
- Renal
- Gastrointestinal
- Hepatobiliary
- Pancreatic
- Infection (includes sepsis)
- Inflammatory (e.g., Systemic Inflammatory Response Syndrome (SIRS) / Immune (including autoimmune) (may include anaphylaxis from environmental (e.g., food allergies)
- Hemorrhage that is neither cardiovascular bleeding or a stroke
- Non-CV procedure or surgery
- Trauma
- Suicide
- Non-prescription drug reaction or overdose
- Prescription drug reaction or overdose (may include anaphylaxis)
- Neurological (non-cardiovascular)
- Malignancy
- Other non-CV causes

Undetermined Cause of Death refers to a death not attributable to one of the above categories of CV death or to a non-CV cause.

Occasionally, it may not be possible to determine exact causality when 2 lethal conditions contribute to death equally. In this circumstance all events not due solely to non-CV causes should be adjudicated as CV-related.

All events for which there is “lack of information” (e.g., the only available information is “patient died”) or when there is insufficient supporting information or detail to assign the cause of death should be adjudicated as undetermined cause of death.

Myocardial infarction

General Considerations

The term myocardial infarction (MI) should be used when there is evidence of myocardial necrosis in a clinical setting consistent with myocardial ischemia. In general, the diagnosis of MI requires the combination of:

- Evidence of myocardial necrosis (either changes in cardiac biomarkers or post mortem pathological findings); and
- Supporting information derived from the clinical presentation, electrocardiographic changes, or the results of myocardial or coronary artery imaging

The totality of the clinical, electrocardiographic, and cardiac biomarker information should be considered to determine whether or not a MI has occurred. Specifically, timing and trends in cardiac biomarkers and electrocardiographic information require careful analysis. The adjudication of MI should also take into account the clinical setting in which the event occurs. MI may be adjudicated for an event that has characteristics of a MI but which does not meet the strict definition because biomarker or electrocardiographic results are not available.

Criteria for Myocardial Infarction

a. Clinical Presentation

The clinical presentation should be consistent with diagnosis of myocardial ischemia and infarction. Other findings that might support the diagnosis of MI should be taken into account because a number of conditions are associated with elevations in cardiac biomarkers (e.g., trauma, surgery, pacing, ablation, heart failure, hypertrophic cardiomyopathy, pulmonary embolism, severe pulmonary hypertension, stroke or subarachnoid hemorrhage, infiltrative and inflammatory disorders of cardiac muscle, drug toxicity, burns, critical illness, extreme exertion, and chronic kidney disease). Supporting information can also be considered from myocardial imaging and coronary imaging. The totality of the data may help differentiate acute MI from the background disease process.

b. Biomarker Elevations

For cardiac biomarkers, laboratories should report an upper reference limit (URL). If the 99th percentile of the upper reference limit (URL) from the respective laboratory performing the assay is not available, then the URL for myocardial necrosis from the laboratory should be used. If the 99th percentile of the URL or the URL for myocardial necrosis is not available, the MI decision limit for the particular laboratory should be used as the URL. Laboratories can also report both the 99th percentile of the upper reference limit and the MI decision limit. Reference limits from the laboratory performing the assay are preferred over the manufacturer's listed reference limits in an assay's instructions for use. In general, troponins are preferred. CK-MB should be used if troponins are not available, and total CK may be used in the absence of CK-MB and troponin.

c. Electrocardiogram (ECG) Changes

Electrocardiographic changes can be used to support or confirm a MI. Supporting evidence may be ischemic changes and confirmatory information may be new Q waves.

• ECG manifestations of acute myocardial ischemia (in absence of left ventricular hypertrophy (LVH) and left bundle branch block (LBBB)):

- ST elevation New ST elevation at the J point in two contiguous leads with the cut-points:
 - ≥ 0.1 mV in all leads other than leads V2-V3 where the following cut-points apply:
 - ≥ 0.2 mV in men ≥ 40 years (≥ 0.25 mV in men < 40 years)
 - or ≥ 0.15 mV in women.
- ST depression and T-wave changes:
 - New horizontal or down-sloping ST depression ≥ 0.05 mV in two contiguous leads and/or new T inversion ≥ 0.1 mV in two contiguous leads with prominent R wave or R/S ratio > 1 .
 -

The above ECG criteria illustrate patterns consistent with myocardial ischemia. In patients with abnormal biomarkers, it is recognized that lesser ECG abnormalities may represent an ischemic response and may be accepted under the category of abnormal ECG findings.

• Criteria for pathological Q-wave

- Any Q-wave in leads V2-V3 ≥ 0.02 seconds or QS complex in leads V2 and V3
- Q-wave ≥ 0.03 seconds and ≥ 0.1 mV deep or QS complex in leads I, II, aVL, aVF, or V4-V6 in any two leads of a contiguous lead grouping (I, aVL; V1-V6; II, III, and aVF)

The same criteria are used for supplemental leads V7-V9, and for the Cabrera frontal plane lead grouping.

• ECG changes associated with prior myocardial infarction

- Pathological Q-waves, as defined above
- R-wave ≥ 0.04 seconds in V1-V2 and R/S ≥ 1 with a concordant positive Twave in the absence of a conduction defect

• Criteria for prior myocardial infarction

Any one of the following criteria meets the diagnosis for prior MI:

- Pathological Q waves with or without symptoms in the absence of nonischemic causes
- Imaging evidence of a region of loss of viable myocardium that is thinned and fails to contract, in the absence of a non-ischemic cause
- Pathological findings of a prior myocardial infarction

Silent myocardial infarction:

Definition of relevant ECG abnormalities related to silent MI is the presence of:

Its definition is based on the global MI guidelines currently described as the presence in the ECG of:

- Any Q-wave in leads V2-V3 ≥ 0.02 seconds or QS complex in leads V2 and V3.
- Q-wave ≥ 0.03 seconds and ≥ 0.1 mV deep or QS complex in leads I, II, aVL, aVF, or V4-V6 in any two leads of a contiguous lead grouping (I, aVL, V6; V4-V6; II, III, and aVF).
- R-wave ≥ 0.04 seconds in V1-V2 and R/S ≥ 1 with a concordant positive Twave in the absence of a conduction defect.

An MI will only be classified as silent if 1) the ECG criteria's are fulfilled, 2) the ECG changes were absent from baseline or previous ECGs and 3) no preceding clinical history of MI (including stent thrombosis and other coronary events) during study follow-up occurred and 4) investigator reporting of silent MI.

Stroke and transient ischemic attack

Stroke (ischemic stroke and intracranial haemorrhage)

Stroke is defined as an acute episode of focal or global neurological dysfunction caused by brain, spinal cord, or retinal vascular injury as a result of hemorrhage or infarction.

Classification:

A. Ischemic Stroke

Ischemic stroke is defined as an acute episode of focal cerebral, spinal, or retinal dysfunction caused by infarction of central nervous system tissue. Hemorrhage may be a consequence of ischemic stroke. In this situation, the stroke is an ischemic stroke with hemorrhagic transformation and not a hemorrhagic stroke.

1. Lacunar/Small Vessel (acute infarction in the deep white or gray matter of the cerebrum including the thalamus, mid pons, or deep cerebellum, less than 2 cm on MRI or 1.5 cm on CT scan).
2. Large vessel Atherosclerosis: Infarction distal to $>50\%$ luminal stenosis of a cervical or intracranial artery as revealed by MRA, CTA or ultrasound.
3. Cardioembolism: Stroke attributed to embolism from the chambers or valves of the heart
4. Undetermined source:
 - a. Undetermined due to incomplete evaluation
 - b. Undetermined due to multiple possible causes
 - c. Undetermined after complete evaluation (embolic stroke of undetermined source)
5. Other

B. Hemorrhagic Stroke

Hemorrhagic stroke is defined as an acute episode of focal or global cerebral or spinal dysfunction caused by intraparenchymal, intraventricular, or subarachnoid hemorrhage.

1. Intraparenchymal
 - a. Lobar
 - b. Deep
 - c. Unable to determine
2. Intraventricular expansion
3. Intraventricular
4. Subarachnoid
5. Unable to determine

C. Unclassified Stroke

Unclassified stroke is defined as an acute episode of focal or global neurological dysfunction caused by presumed brain, spinal cord, or retinal vascular injury as a result of hemorrhage or infarction but with insufficient information to allow categorization as A or B.

Stroke Disability

The Modified Rankin Scale (MRS) will be used to assess stroke outcome. The scale consists of grades, from 0 to 6, with 0 corresponding to no symptoms and 6 corresponding to dead. Investigators will measure and score the MRS based on an interview with the patient at the next regular on-site visit after the onset of the stroke. In those cases where MRS assessment occurred within 90 days after the stroke, a repeat MRS-assessment should be performed at the next on-site visit.

Modified Rankin Scale

Scale Disability


- | | |
|---|---|
| 0 | No symptoms at all |
| 1 | No significant disability despite symptoms; able to carry out all usual duties and activities |
| 2 | Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance |
| 3 | Moderate disability; requiring some help, but able to walk without assistance |
| 4 | Moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance |
| 5 | Severe disability; bedridden, incontinent and requiring constant nursing care and attention |
| 6 | Dead |

Transient Ischemic Attack (TIA)

Transient ischemic attack (TIA) is defined as a transient episode of neurological dysfunction caused by focal brain, spinal cord, or retinal ischemia, *without* acute infarction.

Figure S1

Patient Recruitment and Disposition (CONSORT Diagram)



Incomplete follow-up for the primary end point refers to incomplete information on either vital status or hospitalization until the planned end of the treatment period for those patients who had not experienced an adjudicated primary outcome. The 21 patients without known vital status at the end of the trial included 11 on empagliflozin and 10 on placebo. Three patients with missing vital status at the end of the trial experienced an adjudicated hospitalization for heart failure and are not considered to have incomplete follow-up for the primary endpoint.

Figure S2

Cumulative Incidence for Time to First Hospitalization for Heart Failure




Figure S3

Cumulative Incidence for Time to Cardiovascular Death





Figure S4

Influence of Region on the Effect of Empagliflozin on the Primary End Point



Region “other” refers to Australia and India

Figure S5

Cumulative Incidence for Time to Death for Any Reason




Table S1**Reasons that screened patients were not randomized**

	Total, N (%)
Number of patients screened	7220
Number of patients not randomized	3490 (100.0)
Adverse event	21 (0.6)
Lost to follow-up	19 (0.5)
Consent withdrawn (not due to adverse event)	80 (2.3)
Inclusion / exclusion criteria not met*	3314 (95.0)
Criteria for NT-proBNP not met	2603 (74.6)
Criteria on ejection fraction not met	184 (5.3)
Systolic blood pressure at baseline out of range of eligibility	134 (3.8)
Any other clinical condition unsafe for participation that would jeopardize patient safety while participating in this clinical trial	91 (2.6)
Patient with unstable conditions	56 (1.6)
Renal insufficiency or renal impairment	55 (1.6)
No chronic heart failure or not NYHA class II-IV	39 (1.1)
Any severe (obstructive or regurgitant) valvular heart disease or any valvular disease expected to lead to surgery during the trial in the opinion of the investigator	35 (1.0)
Use of inappropriate medical device, device implanted recently or intent to implant	28 (0.8)
Indication of liver disease	26 (0.7)
Hemoglobin at screening out of range	24 (0.7)
Documented or active malignancy	18 (0.5)
Atrial fibrillation or atrial flutter with a resting heart rate >110bpm	16 (0.5)
Relevant alcohol or drug abuse and other conditions affecting study compliance	16 (0.5)
Treatment with any SGLT2 inhibitor	13 (0.4)
Patients with cardiomyopathies as defined in the protocol	9 (0.3)
Informed consent too late	8 (0.2)
Recently implanted (or intent to implant) ICD or CRT	8 (0.2)
Intake of an investigational drug in another trial within 30 days prior to intake of study medication in this trial	4 (0.1)
Specific inclusion criterion for women of child-bearing potential not met	4 (0.1)
Life expectancy of <1 year in the opinion of the investigator	3 (0.1)
Age out of range of eligibility	2 (0.1)
History of ketoacidosis	2 (0.1)
Currently implanted left ventricular assist device	1 (<0.1)
Diagnosis of peripartum or chemotherapy-related cardiomyopathy	1 (<0.1)
Informed consent not available	1 (<0.1)
Intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial	1 (<0.1)
Missing	69 (2.0)
Other	56 (1.6)

* Patients may have had more than one reason for exclusion. Abbreviations: NT-proBNP = N-terminal prohormone B-type natriuretic peptide; NYHA= New York Heart Association; SGLT2 = sodium-glucose cotransporter 2; ICD = implantable cardioverter-defibrillation; CRT= cardiac resynchronization therapy.

Table S2**Selected Adverse Events of Interest**

	Empagliflozin (n=1863)	Placebo (n=1863)
	N (%)	N (%)
Patients with any adverse event	1420 (76.2)	1463 (78.5)
Patients with any serious adverse event	772 (41.4)	896 (48.1)

Selected adverse events of interest

Hypotension	176 (9.4)	163 (8.7)
Symptomatic hypotension	106 (5.7)	103 (5.5)
Volume depletion	197 (10.6)	184 (9.9)
Ketoacidosis	0 (0.0)	0 (0.0)
Hypoglycemic events*	27 (1.4)	28 (1.5)
In patients with type 2 diabetes	20 (2.2)	22 (2.4)
In patients without type 2 diabetes	7 (0.7)	6 (0.6)
Urinary tract infections	91 (4.9)	83 (4.5)
Complicated urinary tract infections	19 (1.0)	15 (0.8)
Genital infections	31 (1.7)	12 (0.6)
Complicated genital infections	6 (0.3)	5 (0.3)
Bone fractures	45 (2.4)	42 (2.3)
Events leading to lower limb amputation	13 (0.7)	10 (0.5)

Shown are adverse events up to 7 days following discontinuation of study medication, but patients were followed for the occurrence of lower limb amputations up to the end of the trial.

* Hypoglycemic AEs with a plasma glucose value of ≤ 70 mg/dL or that required assistance

Table S3**Sensitivity Analyses for Hierarchically-Tested End Points**

Composite of time to first event of cardiovascular death or hospitalization for heart failure	Hazard ratio (95% confidence interval)
Primary analysis	0.75 (0.65 – 0.86)
Multiple imputations analysis addressing incomplete data in 42 patients for the primary endpoint *	0.75 (0.66 – 0.87)
Results unadjusted for covariates	0.75 (0.66 – 0.86)
Subdistribution hazard ratio adjusting for noncardiovascular death as a competing risk (Fine-Gray) **	0.75 (0.66 – 0.86)
Total hospitalizations for heart failure ***	Hazard ratio (95% confidence interval)
Primary analysis (joint frailty model with cardiovascular death as a competing risk)	0.70 (0.58 – 0.85)
Results unadjusted for covariates #	0.69 (0.57 – 0.84)
Using a joint frailty model with all-cause mortality instead of cardiovascular death as a competing risk	0.70 (0.58 – 0.85)
Slope of change in estimated glomerular filtration rate	Difference in slope (95% confidence interval)
Primary analysis	1.73 (1.10 – 2.37)
Results unadjusted for covariates #	1.79 (1.15 – 2.44)
Using a shared random effects model with all-cause mortality considered as a competing risk **** #	1.55 (0.92 – 2.19)

Confidence intervals of hazard ratios that exclude 1.0 and confidence intervals of differences in slope that exclude 0 are indicative of a treatment effect. # indicates a post-hoc analysis. * Imputations were performed for 42 patients with incomplete data (20 placebo, 22 empagliflozin). Treatment specific incidence rates for empagliflozin and placebo for patients who discontinued study medication with available follow-up data were used to impute the primary events in a multiple imputations framework via sampling from an exponential distribution. One hundred imputations were performed and evaluated by the primary model. Log hazard ratios were summarized by Rubin's rules. ** Fine JP, Gray RJ. J Am Stat Assoc 1999;94:496–509. *** Results from joint model with cardiovascular death or all-cause mortality. (Rogers JK, et al. Stat Med. 2016;35:2195-2205.) **** Joint model for estimated glomerular filtration rate (GFR) intercept and slopes with Weibull model for time to all-cause mortality. Fixed terms for treatment, treatment-by-time, baseline and baseline-by-time included in estimated GFR part of model. Random effects for estimated GFR intercept and slope as well as fixed effect of treatment are included in Weibull part of model. Based on Vonesh E, et al. Stat Med 2006; 25:143–163

Table S4**Comparison of Baseline Characteristics of the Patients Who Participated in the EMPEROR-Reduced and DAPA-HF Trials**

	EMPEROR-Reduced		DAPA-HF
	Empagliflozin (n=1863)	Placebo (n=1867)	Dapagliflozin (n=2373)
Age (yr)	67.2 ± 10.8	66.5 ± 11.2	66.2 ± 11.0
Women (%)	437 (23.5)	456 (24.4)	564 (23.8)
Diabetes mellitus (%)	927 (49.8)	929 (49.8)	993 (41.8)
Ischemic cardiomyopathy (%)	983 (52.8)	946 (50.7)	1316 (55.5%)
NYHA functional class II (%)	1399 (75.1)	1401 (75.0)	1606 (67.7%)
LV ejection fraction (%)	27.7 ± 6.0 (72% ≤30%)	27.2 ± 6.1 (75% ≤30%)	31.2±6.7
NT-proBNP (median, IQR), pg/mL	1887 (1077, 3429) (79% ≥1000)	1926 (1153, 3525) (80% ≥1000)	1428 (857-2655)
Hospitalization for heart failure within 12 months	577 (31.0)	574 (30.7)	647 (27.3)
Atrial fibrillation	664 (35.6)	705 (37.8)	916 (38.6)
Glomerular filtration rate (ml/min/1.73 m ²)	61.8 ± 21.7	62.2 ± 21.5	66.0 ± 19.6
Treatment for heart failure			
RAS inhibitor without neprilysin inhibitor	1314 (70.5)	1286 (68.9)	2007 (84.6)
RAS inhibitor with neprilysin inhibitor	340 (18.3)	387 (20.7)	250 (10.5)
Mineralocorticoid receptor antagonist	1306 (70.1)	1355 (72.6)	1696 (71.5)
Beta blocker	1765 (94.7)	1768 (94.7)	2278 (96.0)
Implantable cardioverter-defibrillator	578 (31.0)	593 (31.8)	622 (26.2%)
Cardiac resynchronization therapy	220 (11.8)	222 (11.9)	190 (8.0%)

For the DAPA-HF trial, only the values for the dapagliflozin arm are shown, since (because it was a randomized trial) the baseline values in the placebo and dapagliflozin arms were very similar. NYHA = New York Heart Association; IQR = interquartile range; LV= left ventricular; NT-proBNP = N-terminal prohormone B-type natriuretic peptide. RAS = renin-angiotensin system. RAS inhibitor with neprilysin inhibitor refers to sacubitril/valsartan. The proportion of patients hospitalized for heart failure within 12 months in the dapagliflozin group in the DAPA-HF trial is derived from McMurray et al, Eur J Heart Fail. 2019;21:1402-1411 and is corrected from a previous version of this table that was posted online at the time of original publication.